An interventional study of OPC-61815 injection 2mg and OPC-61815 injection 4mg in Congestive Heart Failure, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2021-07-28.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Heart Failure by Otsuka Holdings Co., Ltd. — none open to participants now, 1 under way, none of them phase 3. Heart Failure · Otsuka Holdings Co., Ltd..
Among the 17 studies in Heart Failure by Otsuka Holdings Co., Ltd., this one is the 9th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2017, is one of 2 with no phase, and was the 9th registered.
6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.
Browse Heart Failure studies →None of the 17 studies in Heart Failure by Otsuka Holdings Co., Ltd. is open now. The open studies under Heart Failure, anywhere →
Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 20 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2017.
This study's enrollment of 61 is below the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 81 across the 16 interventional studies, 1,600 across the 1 observational. Of the 15 that completed or were terminated, 8 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Heart Failure by Otsuka Holdings Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The dose for intravenous administration of OPC-61815 achieving tolvaptan exposure equivalent to that for oral administration of tolvaptan 15-mg tablet will be investigated by administering OPC-61815 injection 2 to 16mg or tolvaptan 15-mg oral tablet to subjects with congestive heart failure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects who are currently on treatment with any of the following diuretics
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 2 mg.
Drug: OPC-61815 injection 2mg
Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 4 mg.
Drug: OPC-61815 injection 4mg
Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 8 mg.
Drug: OPC-61815 injection 8mg
Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg.
Drug: OPC-61815 injection 16mg
Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo.
Drug: Tolvaptan tablet 15mg
Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 2 mg.
Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 4 mg.
Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 8 mg.
Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg.
Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo.
Maximum Plasma Concentration (Cmax) of OPC-41061 on Day 1
Time frame: Baseline, 1, 1.5, 2, 4, 6, 12 24 hours after the start of administration of investigational drug
Area Under the Concentration-time Curve From Time Zero to 24 Hours (AUC24h) on Day 1
Time frame: Baseline, 1, 1.5, 2, 4, 6, 12 24 hours after the start of administration of investigational drug
| Milestone | OPC-61815 Injection 2mg | OPC-61815 Injection 4mg | OPC-61815 Injection 8mg | OPC-61815 Injection 16mg | Tolvaptan Tablet 15mg |
|---|---|---|---|---|---|
| Started | 13 | 12 | 12 | 12 | 12 |
| Received treatment | 13 | 12 | 12 | 11 | 12 |
| Completed | 13 | 10 | 12 | 11 | 9 |
| Not completed | 0 | 2 | 0 | 1 | 3 |
| Withdrew: Adverse event | 0 | 2 | 0 | 1 | 1 |
| Withdrew: Ast/alt is increased to 3 times upper limit of normal or higher | 0 | 0 | 0 | 0 | 2 |
| ng/mL | OPC-61815 Injection 2mg | OPC-61815 Injection 4mg | OPC-61815 Injection 8mg | OPC-61815 Injection 16mg | Tolvaptan Tablet 15mg |
|---|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of OPC-41061 on Day 1 | 41.4 ± 11.4 | 98.6 ± 43.7 | 149 ± 61.7 | 282 ± 96.0 | 325 ± 194 |
| ng*h/mL | OPC-61815 Injection 2mg | OPC-61815 Injection 4mg | OPC-61815 Injection 8mg | OPC-61815 Injection 16mg | Tolvaptan Tablet 15mg |
|---|---|---|---|---|---|
| Area Under the Concentration-time Curve From Time Zero to 24 Hours (AUC24h) on Day 1 | 356 ± 157 | 983 ± 563 | 1340 ± 522 | 2400 ± 1030 | 2850 ± 1580 |
Collected over Treatment-emergent adverse events (TEAEs) were collected from the start of IMP administration up to 15 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OPC-61815 Injection 2mg | 0/13 (0%) | 0/13 (0%) | 7/13 (53.8%) |
| OPC-61815 Injection 4mg | 0/12 (0%) | 1/12 (8.3%) | 7/12 (58.3%) |
| OPC-61815 Injection 8mg | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| OPC-61815 Injection 16mg | 0/11 (0%) | 0/11 (0%) | 8/11 (72.7%) |
| Tolvaptan Tablet 15mg | 0/12 (0%) | 0/12 (0%) | 10/12 (83.3%) |
| Event | OPC-61815 Injection 2mg | OPC-61815 Injection 4mg | OPC-61815 Injection 8mg | OPC-61815 Injection 16mg | Tolvaptan Tablet 15mg |
|---|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/13 | 1/12 | 0/12 | 0/11 | 0/12 |
| EndocarditisInfections and infestations | 0/13 | 1/12 | 0/12 | 0/11 | 0/12 |
| Event | OPC-61815 Injection 2mg | OPC-61815 Injection 4mg | OPC-61815 Injection 8mg | OPC-61815 Injection 16mg | Tolvaptan Tablet 15mg |
|---|---|---|---|---|---|
| Vessel puncture site reactionGeneral disorders | 0/13 | 2/12 | 0/12 | 0/11 | 0/12 |
| HyperuricaemiaMetabolism and nutrition disorders | 0/13 | 0/12 | 0/12 | 0/11 | 2/12 |
| Dry eyeEye disorders | 0/13 | 0/12 | 0/12 | 1/11 | 0/12 |
| Infusion site extravasationGeneral disorders | 0/13 | 0/12 | 0/12 | 1/11 | 0/12 |
| NasopharyngitisInfections and infestations | 0/13 | 0/12 | 0/12 | 1/11 | 0/12 |
| Vascular access site painInjury, poisoning and procedural complications | 0/13 | 0/12 | 0/12 | 1/11 | 0/12 |
| Blood creatinine increasedInvestigations | 0/13 | 0/12 | 1/12 | 1/11 | 0/12 |
| Blood urea increasedInvestigations | 0/13 | 0/12 | 1/12 | 1/11 | 1/12 |
| Back painMusculoskeletal and connective tissue disorders | 0/13 | 0/12 | 0/12 | 1/11 | 0/12 |
| HeadacheNervous system disorders | 0/13 | 1/12 | 0/12 | 1/11 | 0/12 |
Safety Analysis Set: all subjects treated with the investigational medicinal product (IMP) at least once
| Age, Continuous(years) | OPC-61815 Injection 2mg | OPC-61815 Injection 4mg | OPC-61815 Injection 8mg | OPC-61815 Injection 16mg | Tolvaptan Tablet 15mg | Total |
|---|---|---|---|---|---|---|
| Mean | 73.7 ± 9.5 | 74.5 ± 11.9 | 72.2 ± 9.9 | 77.9 ± 3.8 | 74.8 ± 8.9 | 74.6 ± 9.1 |
| Sex: Female, Male(Participants) | OPC-61815 Injection 2mg | OPC-61815 Injection 4mg | OPC-61815 Injection 8mg | OPC-61815 Injection 16mg | Tolvaptan Tablet 15mg | Total |
|---|---|---|---|---|---|---|
| Female | 5 | 4 | 5 | 3 | 2 | 19 |
| Male | 8 | 8 | 7 | 8 | 10 | 41 |
| Race/Ethnicity, Customized(Participants) | OPC-61815 Injection 2mg | OPC-61815 Injection 4mg | OPC-61815 Injection 8mg | OPC-61815 Injection 16mg | Tolvaptan Tablet 15mg | Total |
|---|---|---|---|---|---|---|
| Asian | 13 | 12 | 12 | 11 | 12 | 60 |
| Region of Enrollment(Participants) | OPC-61815 Injection 2mg | OPC-61815 Injection 4mg | OPC-61815 Injection 8mg | OPC-61815 Injection 16mg | Tolvaptan Tablet 15mg | Total |
|---|---|---|---|---|---|---|
| Japan | 13 | 12 | 12 | 11 | 12 | 60 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.
Ran from Nov 2017 to primary completion in Apr 2018, 5 months.
Results were first posted in Jul 2021, 3 years 3 months after primary completion.
Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 62. This study's 5 months is below that.
Counting every sponsor, half of 1,354 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: OPC-61815
Otsuka Pharmaceutical Co., Ltd. →